- Home
- NRIM vs LENZ Comparison
NRIM vs LENZ Comparison
Compare NRIM & LENZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NRIM | LENZ |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 655.9M | 609.5M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | NRIM | LENZ |
|---|---|---|
| Price | $24.11 | $20.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $56.25 |
| AVG Volume (30 Days) | 173.4K | ★ 1.1M |
| Earning Date | 01-23-2026 | 03-18-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | ★ 73.41 | N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $208,902,000.00 | $17,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.38 | $203.46 |
| P/E Ratio | $8.80 | ★ N/A |
| Revenue Growth | ★ 37.50 | N/A |
| 52 Week Low | $16.18 | $14.43 |
| 52 Week High | $30.82 | $50.40 |
Technical Indicators
Market Signals| Indicator | NRIM | LENZ |
|---|---|---|
| Relative Strength Index (RSI) | 33.33 | 54.39 |
| Support Level | $28.22 | $19.02 |
| Resistance Level | $30.82 | $21.80 |
| Average True Range (ATR) | 1.17 | 1.46 |
| MACD | -0.38 | 0.84 |
| Stochastic Oscillator | 7.88 | 76.93 |
Price Performance
Historical ComparisonAbout NRIM Northrim BanCorp Inc
Northrim BanCorp Inc is a bank holding company. The Company operates in three reportable segments: Community Banking, Home Mortgage Lending, and Specialty Finance. It generates maximum revenue from the Community Banking segment which offers loan and deposit products to business and consumer customers in its market areas and operates nearly 20 branches throughout Alaska.
About LENZ LENZ Therapeutics Inc.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.